Last $297.55 USD
Change Today +3.01 / 1.02%
Volume 2.0
RHHVF On Other Exchanges
SIX Swiss Ex
SIX Swiss Ex
As of 12:13 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-genusschein (RHHVF) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/24/14 - $340.18
52 Week Low
09/16/13 - $253.85
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

roche holding ag-genusschein (RHHVF) Related Bloomberg News

View More Bloomberg News

roche holding ag-genusschein (RHHVF) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate for treating non-small-cell lung cancer; and a collaboration agreement with AmorChem L.P. to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 or Steinert's disease. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holding ag-genusschein (RHHVF) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holding ag-genusschein (RHHVF) Key Developments

Roche Commences Phase III Trials for Investigational Geographic Atrophy Drug Lampalizumab

Roche announced that it has commenced Phase III trials of lampalizumab, a candidate drug for the treatment of geographic atrophy (GA). The Phase III programme will be assessing the safety and efficacy of lampalizumab as well as the drug's potential for slowing GA progression. Additionally, the studies will investigate whether lampalizumab treatment could potentially be more beneficial for people with a mutation in complement factor I, a genetic biomarker. The initiation on the Phase III programme comes after the company announced positive results from the Phase II MAHALO studies in 2013. The Phase II study, which met its primary endpoint, showed that lampalizumab was associated with a 20.4% reduction rate in the area of GA at 18 months. GA is an advanced form of age-related macular degeneration (AMD), affecting more than five million people globally. The Phase III studies - Chroma (GX29176) and Spectri (GX29185) - are identically designed, double-masked, randomised studies, each including 936 patients, evaluating lampalizumab 10mg administered every four or six weeks by intravitreal injection in comparison to sham injections. The primary aim of the trials is to show a reduction in the rate of GA disease progression.

Roche's RoACTEMRA Receives Approval from the European Commission

Roche announced that RoACTEMRA (tocilizumab) has received approval from the European Commission for use in patients with severe, active and progressive RA who previously has not been treated with methotrexate (MTX). Treating the disease at this critical early phase may prevent irreversible damage to joints and long-term disability. 1,2 RoACTEMRA is the first interleukin-6 (IL-6) receptor antagonist to be approved for use in Europe in patients with early RA. The approval was based on data from the phase III FUNCTION study, which assessed the efficacy, safety and prevention of structural joint damage in patients with early moderate-to-severe RA (defined as =2 years since diagnosis) not previously treated with MTX.1 The study met its primary endpoint, demonstrating that patients who received RoACTEMRA in combination with MTX or as a single agent therapy (monotherapy) experienced a significantly greater improvement in disease activity (DAS28 remission) after 24 weeks compared to patients who received MTX alone.

Art Levinson Resigns from the Board of Roche

Former Genentech CEO Art Levinson severed his last formal tie to the biotech powerhouse, by resigning from the board of parent company Roche. Roche said Levinson made the decision to avoid any conflict of interest with his new company. Levinson is CEO of Calico and late last year lured Dr. Hal Barron, Genentech's chief medical officer, to the new venture as well. Meanwhile, Calico is starting to ramp up hiring - one source said it is looking to hire as many as 150 people - and at least some of those are likely to current Genentech employees.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHHVF:US $297.55 USD +3.01

RHHVF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $26.25 USD +0.325
Gilead Sciences Inc $104.29 USD +3.30
Merck & Co Inc $59.99 USD +0.47
Novartis AG SFr.87.75 CHF -0.35
Pfizer Inc $30.06 USD +0.14
View Industry Companies

Industry Analysis


Industry Average

Valuation RHHVF Industry Range
Price/Earnings 21.0x
Price/Sales 4.6x
Price/Book 12.8x
Price/Cash Flow 17.1x
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-GENUSSCHEIN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at